[144] BridgeBio Pharma, Inc. SEC Filing

Rhea-AI Filing Summary

BridgeBio Pharma, Inc. (BBIO) – Form 144 notice of proposed sale

This filing informs the SEC of an intended insider sale under Rule 144:

• Securities: Common Stock
• Shares to be sold: 100,000
• Aggregate market value: $4,422,803.30
• Portion of outstanding: ≈0.05% of the 189,880,720 shares outstanding
• Broker: Merrill Lynch, 555 California St, 18th Fl, San Francisco, CA 94104
• Planned sale date: 24 Jun 2025 on Nasdaq
• How acquired: 200,000-share stock bonus received 1 Oct 2021 from BridgeBio Pharma
• No sales by the filer during the past three months.

The signer attests that no undisclosed material adverse information is known. The notice authorises—but does not require—sales within the next 90 days.

Positive

• None.

Negative

• Insider intends to sell 100,000 BBIO shares valued at $4.42 M, potentially signaling reduced executive sentiment.

Insights

Securities Analyst

TL;DR Insider plans to sell 100k BBIO shares (~$4.4 M), a routine 0.05% of float; market impact likely minimal.

The Form 144 signals an affiliate’s intention to dispose of 100,000 BridgeBio shares at an estimated value of $4.42 million. Relative to the 189.9 million shares outstanding, the stake is de-minimis, representing roughly 0.05% of issued equity. Acquisition via a 200,000-share stock bonus suggests compensation-related ownership rather than a broad strategic divestiture. No prior sales in the last three months temper concerns over persistent selling pressure. Rule 144 filings are procedural; execution may or may not occur, and the window is limited to 90 days. Absent other context, the disclosure is judged neutral for valuation, though investors often monitor insider disposition for sentiment cues.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch 555 California St, 18th Fl San Francisco CA 94104	100000	4422803.30	189880720	06/24/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	10/01/2021	Stock Bonus	BridgeBio Pharma			200000	10/01/2021	Stock Bonus

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many BridgeBio Pharma (BBIO) shares are proposed for sale?

The Form 144 covers 100,000 common shares.

What is the estimated market value of the BBIO shares to be sold?

The aggregate value stated is $4,422,803.30.

When can the shares be sold under this Form 144?

The filer lists an approximate sale date of 24 June 2025, within Rule 144’s 90-day window.

How were the shares originally acquired?

They were received on 1 October 2021 as part of a 200,000-share stock bonus from BridgeBio Pharma.

What percentage of BridgeBio’s outstanding shares does the sale represent?

Roughly 0.05% of the 189,880,720 shares outstanding.

Which broker is handling the proposed sale?

The filing lists Merrill Lynch, 555 California St, San Francisco, CA 94104.